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Summary A series of stilbenes, based on combretastatin A-4, were synthesised. A structure-activity study
was carried out to characterise the interaction of these agents with tubulin. The substitution of small alkyl
substituents for the 4'-methoxy group of combretastatin A-4 and the loss of the 3'-hydroxyl group does not
have a major effect on the interaction with tubulin. trans-Stilbenes were shown to bind tubulin, but do not
inhibit microtubule assembly. This work, together with previous studies, has been used to propose an idealised
structure for a tubulin-binding agent of this type.
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The vinca alkaloids are some of the most clinically useful
anti-cancer drugs. These agents are complex natural products
(vincristine, vinblastine) or semisynthetic derivatives (vin-
desine) which have been shown to disrupt intracellular mic-
rotubular structures leading to the failure of chromosome
segregation.
Combretastatin A-4 (1) (Figure 1) (Pettit et al., 1989), a
relatively simple stilbene isolated from the African shrub
Combretwn caffrwn, has been shown to interact with tubulin
with resultant disruption of microtubular function and to
bind to the protein at a site shared, or close to, the colchicine
binding site. The latter action is not shared with the vinca
alkaloids (McGown and Fox, 1989). This work also sug-
gested that a bicycic structure, in which two planar rings are
tilted at 50-60° to each other, is an important structural
feature for binding to the colchicine site on tubulin.
The present study was carried out to investigate further the
structural features involved in the interaction of combretas-
tatin analogues with tubulin. To this end, a series of 4'-alkyl
and fluoroalkyl derivatives of combretastatin (Figure 2) were
synthesised and tested for their interactions with purified
tubulin. Similarly, the effects ofthese agents on the growth of
A2780 human ovarian tumour cells and P388 mouse
leukaemia cells, together with their multidrug-resistant sub-
lines, were studied in vitro. This study is complementary to
that of Cushman et al. (1992).
Materials and methods
Chemicals
Combretastatin A-4 (1) was synthesised in our laboratories
(Pettit et al., 1989). Synthetic intermediates were used as
received from Aldrich, Kodak or Lancaster Synthesis. Tetra-
hydrofuran was dried over calcium hydride and chromato-
graphic solvents were distilled before use. Nuclear magnetic
resonance (NMR) spectra were determined on Bruker AC300
or Jeol EX270 spectrometers in deuterochloroform (unless
otherwise stated) and are referenced (6) to tetramethylsilane.
Electron impact mass spectra were recorded on a VG Trio 2
mass spectrometer at an ionising energy of 70 eV. Melting
points were measured on a Kofler block and are uncorrected.
General method
To a stirred suspension of 3,4,5-trimethoxybenzyltriphenyl
phosphonium bromide (2) (250 mg, 0.478 mM; Pettit et al.,
1987) in dry tetrahydrofuran (THF, 10ml) under argon at
-15C was added n-butyl-lithium (0.33 ml, 1.6 M solution in
hexanes, 0.528 mM). After stirring at room temperature for
0.5 h, a para-substituted aldehyde (0.478 mM) was added.
After 0.5 h ice-water (5 ml) was added and the mixture
extracted with ether (3 x 5 ml). The combined organic ex-
tracts were washed with water (2 x 5 ml) and brine (2 x 5 ml)
and dried (magnesium sulphate). Removal of the solvent
afforded two stilbenes which were separated by flash
chromatography (petroleum ether 60-80°/ethyl acetate,
85:15) as homogeneous compounds. In each case the Z-
isomer had the higher RF value. Using this method the
following compounds were prepared.
cis-3,4,5-Trimethoxy-4'-methylstilbene (3a)
Isolated as an oil (40%). NMR: 2.31 (3 H, s, ArMe); 3.70
(6 H, s, 2 x OMe); 3.85 (3 H, s, OMe); 6.50 (2 H, s, 2,
6-ArH); 6.45 (1 H, d, J= 12.3 Hz, = C-H); 6.57 (1 H, d,
J = 12.3 Hz, = C-H); 7.07 (2 H, d, J = 8 Hz); 7.20 (2 H, d,
J = 8 Hz). M+, 284 (100%), 269 (M-CH3, 81%) (Cushman
et al., 1992).
trans-3,4,5-Trimethoxy4'-methylstilbene (3b)
Isolated as a solid (33%). m.p. 126.5-128C (lit. m.p.
125-127°C; Cushman et al., 1992) (from petroleum ether).
NMR acetone-d6): 2.45 (3 H, s, Me); 3.81 (3 H, s, OMe); 3.97
(6 H, s, 2 x OMe); 7.01 (2 H, s, 2,6-H); 7.20 (1 H, d,
J = 16Hz, =C-H); 7.28 (2H, d, J=8 Hz); 7.29 (1 H, d,
J= 16Hz, =C-H); 7.55 (2H, d, J=8Hz). M+, 284
(100%), 269 (M-CH3, 68%).
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Figure 2 Synthesis of stilbenes (3-7).
cis-3,4,5-Trimethoxy-4'-ethylstilbene (4a)
Isolated as an oil (45%). NMR: 1.20 (3 H, t, J = 7.5 Hz,
CH3-CH2); 2.66 (2 H, q, J = 7.5 Hz, CH3-CH2); 3.68 (6 H,
s, 2 x OMe); 3.84 (3 H, s, OMe); 6.48 (2 H, d, J= 12 Hz,
= C-H); 6.59 (1 H, d, J = 12 Hz, = C-H); 7.10 (2 H, d,
J = 8 Hz); 7.22 (2 H, d, J = 8 Hz). M+, 298 (100%), 283
(M-CH3, 81%) (Cushman et al., 1992).
trans-3,4,5-Trimethoxy-4'-ethylstilbene (4b)
Isolated as a solid. m.p. 99-101C (lit. m.p. 98-100C; Cush-
man et al., 1992) (from petroleum ether). NMR acetone-d6):
1.31 (3 H, t, J = 7.5 Hz, CH3-CH2); 2.73 (2 H, q, J = 7.5 Hz,
CH3-CH2); 3.82 (3 H, s, OMe); 3.98 (6 H, s, 2 x OMe); 7.01
(2 H, s, 2,6-H); 7.21 (1 H, d, J = 16 Hz, = C-H); 7.31 (2 H,
d, J = 8 Hz); 7.57 (2 H, d, J = 8 Hz). M+, 298 (100%), 283
(M-CH3, 72%).
cis-3,4,5-Trimethoxy-4'-n-propylstilbene (5a)
Isolated as an oil (40%). NMR (acetone-d6): 0.92 (3 H, t,
J = 8 Hz, CH3-CH2); 1.56-1.64 (2 H, m, CH3CH2; 2.58
(2 H, t, J = 8 Hz, ArCH2); 3.62 (6 H, s, 2 x OMe); 3.70 (3 H,
s, OMe); 6.50 (1 H, d, J = 12.2 Hz, = C-H); 6.54 (2 H, s,
2,6-ArH); 6.58 (1 H, d, J = 12.2 Hz, = C-H); 7.14 (2 H, d,
J = 8 Hz); 7.22 (2 H, d, J = 8 Hz).
trans-3,4,5-Trimethoxy-4'-n-propylstilbene (Sb)
Isolated as an oil (43%). NMR: 0.95 (3 H, t, J = 7 Hz,
CH3CH2); 1.58-1.75 (2 H, m, CH3CH2); 2.60 (2 H, t,
J = 7 Hz, ArCH2); 3.75 (3 H, s, OMe); 3.88 (6 H, s,
2 x OMe); 6.90 (2 H, s, 2,6-H); 7.12 (1 H, d, J = 16 Hz,
= C-H); 7.19 (1 H, d, J = 16 Hz, = C-H); 7.20 (2 H, d,
J = 8 Hz); 7.48 (2 H, d, J = 8 Hz). M+, 312 (100%); 297
(M-CH3, 63%).
cis-3,4,5-Trimethoxy-4'-isopropylstilbene (6a)
Isolated as an oil (31%). NMR: 1.22 [6 H, d, J=7 Hz,
(CH3)2-CH]; 2.88 [1 H, septet, J = 7 Hz, (CH3)-CMJ; 3.64
(6 H, s, 2 x OMe); 3.84 (3 H, s, OMe); 6.45 (1 H, d,
J = 12 Hz, =C-H); 6.46 (2 H, s, 2,6-H); 6.59 (1 H, d,
J=12Hz, =C-H); 7.14 (2H, d, J=8Hz); 7.24 (2H, d,
J = 8 Hz). M+, 312 (100%); 297 (M-CH3, 67%) (Cushman
et al., 1992).
trans-3,4,5-Trimethoxy-4'-isopropylstilbene (6b)
Isolated as an oil (20%) which slowly crystallised. m.p.
76-77°C (lit. m.p. 98-100°C; Cushman et al., 1992). NMR
(acetone-d6): 1.32 [6 H, d, J = 6 Hz, (CH3)2-CH]; 2.90 [1 H,
septet, J = 6 Hz, (CH3)2-C!i; 3.88 (3 H, s, OMe); 3.98 (6 H,
s, 2 x OMe); 7.00 (2 H, s, 2,6-H); 7.22 (1 H, d, J = 15.5 Hz,
= CH); 7.30 (1 H, d, J = 15.5 Hz; = CH); 7.34 (2 H, d,
J=8Hz); 7.59 (2H, d, J=8Hz).
cis-3,4,5-Trimethoxy-4'-trifluoromethylstilbene (7a)
Isolated as an oil (48%). NMR: 3.70 (6 H, s, 2 x OMe); 3.90
(3 H, s, OMe); 3.90 (3 H, s, OMe); 6.44 (2 H, s, 2,6-H); 6.63
(1 H, d, J= 13Hz, =C-H); 6.75 (l H, d, J= 13Hz,
= C-H); 7.43 (2 H, d, J = 8 Hz); 7.56 (2 H, d, J= 8 Hz).
M+, 338 (100%); 323 (M-CH3, 98%).
trans-3,4,5-Trimethoxy-4'-trifluoromethylstilbene (7b)
Isolated as an oil (43%). NMR: 3.91 (3 H, s, OMe); 3.99
(6 H, s, 2 x OMe); 6.80 (2 H, s, 2,6-H); 7.06 (1 H, d,
J = 16.5 Hz, = C-H); 7.17 (1 H, d, J = 16.5 Hz, = C-H);
7.65 (4 H, s, 2',3',5',6'-H). M+, 338 (100%); 323 (M-CH3,
20%).
Cell culture
A P388 mouse leukaemia cell line, together with a multidrug-
resistant subline (P388 R8/22) were cultured as described
previously (McGown and Fox, 1990). A human ovarian
carcinoma cell line (A2780) and its multidrug-resistant sub-
line (A2780/ADR) were grown in RPMI medium supple-
mented with 10% fetal calf serum, 1% pyruvate and 0.1%
insulin. All cell lines were mycoplasma free and >95%
viable, as measured by trypan blue exclusion, at the start of
experimentation. Cytotoxicity tests were carried out using the
nBuLi
THF , Cis (a)
H
H
)3Br-MTT asssay (Edmondson et al., 1988). The IDo concentra-
tion was calculated with reference to a standard curve con-
structed for control cells.
Cell cycle analysis anddetermination ofmitotic index
P388 cells were incubated at a coticentration corresponding
to 10 x IDs of the drug for 24 h before fixation [acetone-
ethanol (1:1) as described previously (McGown et al., 1984)].
Mitotic indices were measured by the method ofWolpert-de-
Filipes et al. (1975) using 5% Giemsa stain. One thousand
cells per slide were scored following treatment with the drugs
(1, 0.02fM; 3a, 0.2gtM; 4a, 0.2gsM; 5a, 20lsM; 6a, 241 gM; 7a,
20gM; 3b, 50g4M; 4b, 20lM; 5b, 50gM; 6b, 20gtM; 7b,
50 Mm).
Isolation oftubulin
The procedure was based on a modification ofthe method of
Miglietta et al. (1987). Briefly porcine brain was chilled
within minutes of slaughter and homogenised in isolation
buffer [0.1 M Mes (2-N-morpholinomethansulphonic acid),
1 mM EGTA, 0.5 mM magnesium chloride, pH 6.6] before
isolation by two cycles of assembly-disassembly. This was
further purified (Hamel and Lin, 1984) by addition of 2 M
Mes (pH 6.9) followed by assembly-disassembly, yielding
electrophoretically pure tubulin.
Tubulin assembly-disassembly
The assembly of microtubules from isolated tubulin was
carried out spectrophotometrically at 350 rm and utilised the
increase in turbidity which is associated with microtubule
formation. Assembly was initiated by temperature increase
from 10 to 35C. The effect of drugs on the increase in light
absorption was carried out as described previously (McGown
and Fox, 1989). Drugs were dissolved in dimethyl sulphoxide
(DMSO) (<4%), which did not affect control assembly.
Competitive binding assays
The ability of agents to compete with colchicine for binding
to tubulin was examined by a spun column method (Na and
Timasheff, 1986). Briefly, tubulin (51M) was incubated with
test compound and colchicine (10 iM, spiked with [3H]-
colchicine, 20 nCiml-') for 90 min in buffer (0.1 M Mes,
1 mM EGTA, 1 mM EDTA, 1 mM magnesium chloride,
pH 6.8). The mixture was loaded on to previously prepared
columns of 1 ml of G50 Sephadex (in 40mM Mes, 40mM
Tris, 1 mM magnesium sulphate, pH 7.5, 11.5 ml g Sepha-
dex). These were centrifuged (900g, 2 min) and the eluent
analysed by liquid scintillation counting using Ecoscint
(National Diagnostics, NJ, USA). When tubulin was not
present negligible levels of [H]colchicine were detected
(1 ± 1% of control values) indicating that the free (non-
protein bound colchicine) compound is not absorbed by the
Sephadex. Therefore, all radioactivity arises from tubulin-
bound colchicine. All experiments were performed in trip-
licate.
Affinity constant andfree energy ofbinding
The analyses were carried out based on the method of
Prakash and Timasheff (1983) as described previously
(McGown and Fox, 1989). The assay utilises the change in
protein (tubulin) fluorescence which occurs upon binding of
drugs. Analysis of these data yields both the dissociation
constant and the free energy of drug-protein binding.
Tubulin (1 gM) was incubated with various drug concen-
trations (covering drug-protein ratios of between 0.1 and 20
in 0.1 M Mes buffer, pH 6.4) for 90 min at room temperature
in the dark. The samples were placed on ice before protein
fluorescence was analysed (Shimadzu RF540 fluorimeter
Ax = 275 nm, A1m = 328 nm). All experiments were performed
in duplicate.
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Immunocytochemistry
The intracellular distribution of microtubules following treat-
ment with drugs was determined using a modification of the
method of Fuller and Brinkley (1975). Studies were carried
out on Vero cells because of their large cytoplasms and
extensive microtubular networks. Drugs were added (50JLM)
and the cells incubated in eight-well chamber slides (NUNC,
Naperville, USA) for 40 min at 37°C, followed by fixation in
paraformaldehyde (3.5% in PBS) for 10 min. The cells were
then permeabilised (50:50 ethanol-acetone, - 20°C, 7min),
washed, and the free aldehyde groups reduced by borohy-
dride (5 mgml 1, 3 x 5 min washes). Before analysis by
fluoresccence microscopy the slides were then blocked (0.1%
bovine serum albumin, 20mM sodium azide, 40min, 37°C)
and stained in a two-step process with a primary antibody
against P-tubulin at 1:20 dilution for 70min at 37°C followed
by visualisation with a fluorescein isothiocyanate (FITC)-
conjugated secondary antibody (Boehringer) (50min, 37°C,
1:20 dilution).
Results
The stilbenes (3-7) were prepared in high yield by treating
the phosphonium bromide (2) with n-butyl-lithium in THF
followed by the addition of a p-substituted benzaldehyde
(Scheme). This reaction afforded a closely running mixture of
the cis and trans isomers (3-7), which were separated by
careful chromatography on silica gel. The separated isomers
were homogeneous on thin-layer chromatographic plates
(silica gel), and proton NMR spectroscopy of each of the
isomers indicated their stereochemical and chemical purity.
(To avoid photochemical isomerisation the separated isomers
were kept in the dark.) Proton NMR spectroscopy was used
to establish the stereochemistry of the two separated isomers.
In some cases the olefinic protons only provided a singlet
when determined in deuterochloroform, but the spectra were
resolved using hexadeuteroacetone as solvent. The latter sol-
vent emphasised the coupling of the olefinic protons allowing
the stereochemical assignments.
The effects of the cis-4'-methyl (3a) isomer is shown in
Figure 3. From these data a value for the 50% inhibition of
tubulin assembly was calculated. These data are summarised
in Table I. The maximum concentration used was 50ylM. The
most potent agent was combretastatin A-4 (1), although the
cis-4'-methyl and 4'-ethyl derivatives (3a, 4a) also showed
inhibition of tubulin assembly. The trans isomers (3b-7b)
were all inactive. No trans isomer of combretastain A-4 was
available to carry similar studies.
The affinity of these analogues for tubulin is shown in
Table II. Although combretastatin A-4 (1) has the highest
affinity for tubulin, all the cis analogues (3a-7a) show strong
binding, having dissociation constants in the 0.4-2liM range.
The trans isomers, with the exception of the isopropyl
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Figure 3 Effect of the cis-methyl analogue (3a) on the assembly
of isolated tubulin.Intraclon ofstilbeneswithtubulin
_ JA Woods etal
708
Table I ICo value for the inhibition of tubulin assembly
Cis compound Trans compound
Compound IC50 value (gM) ICs value (gM)
1 2.4 1.4 > 50
3 10.8±2.9 >50
4 7±3 >50
6 >50 >50
7 >50 >50
5 >50 >50
Table II Dissociation constants ofthe 4'-substituted combretastatins
Cis Trans
Dissociation constant Dissociation constant
Compound (Kd) ALM (Kd) guM
1 0.40 0.06 N/A
3 0.75 0.01 3.53 0.74
4 1.22 0.08 2.76 1.34
6 1.52 0.23 83.3
5 0.98±0.16 1.03±0.31
7 2.06 ± 0.05 2.9 ± 0.4
Table III Percentage of [3H]colchicine remaining bound to tubulin
after drug competition
[3HJcolchicine (per cent control d.p.m.)
drug-protein ratio = 10:1
Compound Cis Trans
1 12 1 N/A
3 19.4 ± 2.2 77.3 ± 3.6
4 17.5 ± 1.4 89.7 ± 5.5
5 55.3 ± 8.5 99.7 ± 9.7
6 66.2 8.6 94.3 11.6
7 55.1 ± 7.8 103.8 ± 10.5
110 -
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o 70-_
c 50
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0
0
- 50-
0
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Figure 4 Effect of cis- (0) and trans-methyl (a) analogues
(3a,3b) on the binding of colchicine to isolated tubulin. a,
Control; 0, l5ivm; *, IOLM; A, S5AM; X, 2.5,M.
derivative (6b), also showed similar affinities for tubulin.
However, the Kd values of the cis isomers (3a-7a) were
generally lower than those seen for the trans isomers (3b-7b),
particularly in the case of the methyl and ethyl derivatives
(3a,4a), whose Kd values were lower by factors of 8.8 and 6.9
respectively. Little difference is noticeable between the cis and
trans isomers.
The abililty of the cis- and trans-4'-methyl analogues
(3a,3b) to compete with colchicine for binding to tubulin is
shown in Figure 4. Whereas the cis isomer (3a) can inhibit
binding of [3H]colchicine, the trans isomer (3b) shows much
lower activity. A summary of data from all analogues is
shown in Table III, and indicates the loss of colchicine
binding at a fixed ratio of drug to protein (10:1).
The effects of these analogues on the growth of P388
mouse leukaemia cells and A2780 human ovarian carcinoma
cells and their multidrug-resistant sublines (P388R8/22 and
A2780/ADR) in vitro are shown in Table IV. These data
show combretastatin A4 (1) to be the most cytotoxic of the
agents tested against both the mouse leukaemia (P388) and
human ovarian (A2780) cell lines. This agent is equally
potent in the multidrug-resistant cell lines, P388R8/22 and
A2780/ADR. The cis-methyl and ethyl analogues (3a,4a)
were also highly cytotoxic in all cell lines tested. In general,
cytotoxicity decreased with increasing side chain size, with
the bulky isopropyl group showing the lowest inhibition of
cell growth. The trans-isomers (3b-7b) were much less toxic,
and only showed significant growth inhibition at concentra-
tions in the micromolar range.
All cis isomers (3a-7a) tested were found to be capable of
causing cell cycle arrest, with cells completing DNA synthesis
but being unable to undergo cell division (Figure 5).
Evidence of the start offurther DNA synthesis, without prior
cell division, was observed at later times and was seen as cells
with >4n DNA content. The trans isomers (3b-7b) were, in
general, less effective at inducing a G2/M block, only the
trifluoromethyl and ethyl derivatives (7b,4b) causing G2/M
block (Figure 6). The findings ofthese cell cycle studies are in
agreement with the increase in mitotic index seen following
treatment with the cis isomers (3a-7a), and also with the
trans-trifluoromethyl and ethyl isomers (7b,4b) (Table V).
The intracellular network of microtubules seen in un-
Table V Percentage ofcells in mitosis following 12 h treatment with
drug. Control (untreated) cells showed 2% mitoses
Mitoses in P388 cells (%)
Compound Cis Trans
1 15 ND
3 18 1
4 31 24
5 13 2
6 16 9
7 24 9
Table IV Growth inhibition in P388, P388R8/22, A2780 and A2780/ADR cells. Results
show mean ± errors of triplicate experiments
Compound P388 P388R8/22 A2780 A2780/ADR
Cis isomers
1 2.6 1.0 1.2 0.8 0.72 0.23 0.84 0.23
3a 9.1 ±8.1 13.4 6.1 25.8 9.8 23.0 2.0
4a 8.4±4.3 11.0±4.0 56.5 3.5 16.0±3.5
5a ND ND 273±78 179±21
6a 3800 ± 1600 640 ± 120 400 120 400 30
7a ND ND 180±40 155±65
Trans isomers
3b 31 000 8000 17 300 400 1800 700 9400 150
4b 3800 2900 2800 2300 4900 900 3300 330
5b ND ND 2200 1100 7000 100
6b > 50 000 >50 000 >50 000 >50000
7b ND ND 6600 ± 900 11 000± 200
a r l . .. . . . ..... rnrr<Z 10 Z 100
a)
<), 80
o
0
c 60
3 40 uT
0)
o 20
c
a O
0 1000 2000
Time (min)
Figure 5 The accumulation of cells with >4n DNA content
following treatment with the cis isomers (3a-7a). *, Control; x,
1; E, 3a; A, 4a; 0, 5a; Ol, 6a; A, 7a.
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Figure 6 The accumulation of cells with >4n DNA content
following treatment with the trans isomers (3b-7b). 0, DMSO;
*, 3a; A, 4a; 0, 5a; 0, 6a; A, 7a.
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treated cells (Figure 7a) is destroyed by incubation with all
cis isomers (3a-7a) (Figure 7b-g), resulting in the produc-
tion of a diffuse staining pattern when compared with the
control cells. In contrast, treatment with the trans isomers
(3b-7b) does not produce this effect (Figure 7h-1) and the
microtubule structures appear similar to the untreated con-
trols (Figure 7a).
Discussion
The vinca alkaloids are among the most widely used anti-
cancer drugs, showing activity in a number of human malig-
nancies. The mechanism of action of these agents is widely
accepted to involve disruption ofmicrotubule-associated pro-
cesses, particularly the mitotic apparatus. The complexity of
these natural or semisynthetic drugs has restricted the
development of analogues. The naturally occurring com-
bretastatins are much simpler compounds which are suitable
for analogue development via structure-activity studies. We
therefore synthesised and tested a number of stilbenes in
order to examine the effect of the introduction of an alkyl or
fluoroalkyl group in the 4' position of the stilbene.
These results show that combretastatin A-4 (1), the lead
compound, binds strongly to tubulin, is a powerful inhibitor
of tubulin assembly and is a potent cytotoxic agent in vitro.
Replacement of the 4'-methoxy group with a short (methyl
or ethyl) group together with removal of the 3'-hydroxyl
group in the cis conformation does not drastically reduce
interaction with tubulin. Indeed, although combretastatin A-
4 (1) was the most potent of the series tested, the cis-methyl-
and ethyl-stilbenes (3a,4a) have been shown to interact
strongly with tubulin and can inhibit assembly of micro-
tubules, cause disruption of intracellular microtubular struc-
ture and inhibit colchicine binding to tubulin, and are
cytotoxic to cultured cells. This provides evidence that the
4'-methoxy and 3'-hydroxy groups of combretastatin A-4 (1)
are not essential for interaction with tubulin.
A summary ofthese findings is shown in Table VI. Clearly,
the stereochemistry of the ethene bridge is very important.
The trans agents (3h-7b) do not cause inhibition of tubulin
assembly in vitro, are much less cytotoxic than the
a d a i
b e h
f i
k
I
Figure 7 Effect of stilbenes (3-7) on the intracellular organisation of microtubules. (a) Control, (b) combretastat in A-4 (1), (c) 3a,
(d) 7a, (e) 4a, (f) Sa, (g) 6a, (h) 3b, (i) 7b, (j) 4b, (k) 5b, (1) 6b.
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Table VI Comparison of the cis and trans isomers
Property Cis Trans
Assembly inhibition 1>4a>3a>>6a,5a,7a All inactive
Kd 1>3a>5a>4a>6a>7a Sb>4b>7b>3b>6b
Values similar Trans>> Cis
Colchicine displacement 1>4a>3a>>7a,5a,6a 3b>4b,6b,5b,7b
Cis> Trans
Cytotoxicity (P388) 1,3a,4a>>6a 4b>3b>>6b
Cytotoxicity (A2780) 1>3a>4a>7a>5a>6a 3b,5b>4b,7b>>6b
Cis>> Trans
Anatomy of a tubulin binder
MeO v Cisfor binding
Eii~~~ OH MDr
MeO O substrate
OMe Important for binding OH not
(cf. colchicine) essential
R
Essential. Small alkyl groups
do not adversely affect activity
Methoxy group is not essential
Figure 8 Idealised structure of a microtubule-disrupting agent.
corresponding cis isomers (3a-7a) and are not efficient at
competing with colchicine for binding to tubulin. Surpris-
ingly, they do bind to tubulin with dissociation constants and
free energies of binding which are similar to those of cis
isomers (3a-7a). However, their lack of effect on tubulin
assembly and colchicine binding is evidence that the trans
isomers (3b-7b) bind at sites remote from the colchicine/cis-
stilbene binding site. Similarly, whereas the cis isomers
(3a-7a) were shown to cause disruption to intracellular
microtubular networks, the trans isomers (3b-7b) were
ineffective (Figure 7).
In general, increasing the length of the substituent chain
leads to a reduction in binding to tubulin and cytotoxicity for
the more active cis isomers (3a-7a). Interaction with tubulin
is tolerant of the replacement ofthe 4'-methoxy by methyl or
ethyl groups, but significant loss of activity is seen with the
larger propyl or isopropyl gropus and when the electron-
withdrawing trifluoromethyl group is used. It is also interes-
ting to note that, whereas all the cis isomers (3a-7a) caused
a G2/M phase block in the cell cycle and an increase in
mitotic index, the trans-ethyl and -trifluoromethyl isomers
(4b,7b) also showed this effect. This was not reflected in the
cytotoxic effects of the trans agents (4b,7b). Why only these
two agents (4b,7b) cause this block is not known, particularly
as no disruption of the intracellular microtubular network
was observed even at 50gIM. In general, these studies are in
agreement with the report by Cushman et al. (1992) that the
cis-methyl and -ethyl derivatives (3a,4a) inhibit tubulin
assembly. This present study further characterises the interac-
tion of agents of this type with tubulin.
The optimal structure for an agent to bind to the col-
chicine site on tubulin has not yet been fully elucidated.
However, this work, in combination with previous studies,
can allow us to assign certain structural features to biological
activity. The following features have been proposed to be
important:
(a) Two (or more) planar rings tilted with respect to each
other (McGown and Fox, 1989).
(b) The trimethoxy motif on the A ring is common to a
number of agents which are known to interact with
tubulin (colchicine, combretastatins, podophyllotoxins,
steganacin etc.).
(c) The 2'-hydroxyl group has been implicated in multidrug
resistance (MDR) recognition (McGown and Fox,
1989). Omission of this group has been shown to result
in molecules which are not involved in the MDR pro-
cess.
(d) The 3'-hydroxyl group has a relatively small effect on
binding to tubulin (Cushman et al., 1992).
(e) The 4'-methoxy group of combretastatin A-4 (1) can be
replaced with small hydrophobic groups while still
retaining significant activity against tubulin.
(f) The ethene bond must be in the cis configuration.
These are shown schematically in Figure 8.
In conclusion, we have shown that substitution of small
aklyl groups at the 4' position ofcombretastatin A-4 (1) and
loss of the 3'-hydroxyl group does not significantly inhibit
the interaction of these agents with tubulin. The results of
this study have substantially added to our current knowledge
of the structural requirements for tubulin binding.
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